A Phase โ ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
PHASE2
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib...
Status
Recruiting
Location
Beijing Chest Hospital,Capital Medical Unniversity